

# Evolut Clinical Guideline 2044 for Pelvis Magnetic Resonance Angiography (MRA) A/MRV (Angiography/Venography)

<b>Guideline <del>or Policy</del> Number:</b> Evolut_CG_0392044	<b><u>Applicable Codes</u></b>	
<i>"Evolut" refers to Evolut Health LLC and Evolut Specialty Services, Inc.</i> © 2008 - 202 <del>65</del> Evolut. All rights Reserved.		
<b>Original Date:</b> May 2008	<b>Last Revised Date:</b> <del>July</del> May 202 <del>54</del> 5	<b>Implementation Date:</b> January 202 <del>65</del> 5

## TABLE OF CONTENTS

<b>STATEMENT .....</b>	<b>3</b>
GENERAL INFORMATION .....	3
PURPOSE .....	3
SPECIAL NOTE .....	3
<b>INDICATIONS FOR PELVIS MRA .....</b>	<b>3</b>
ABDOMINAL AORTIC DISEASE .....	3
<i>Abdominal Aortic Aneurysm</i> .....	3
<i>Aortic Syndromes</i> .....	4
<i>Postoperative Follow-up of Aortic Repair</i> .....	4
ISCHEMIA OR HEMORRHAGE .....	5
OTHER VASCULAR ABNORMALITIES OF THE PELVIS .....	5
VENOUS DISEASE .....	6
EVALUATION OF TUMOR .....	6
<b>PREOPERATIVE OR POSTOPERATIVE ASSESSMENT .....</b>	<b>7</b>
<b>FURTHER EVALUATION OF INDETERMINATE FINDINGS .....</b>	<b>8</b>
<b>IMAGING OF KNOWN GENETIC CONDITIONS.....</b>	<b>8</b>
COMBINATION STUDIES FOR KNOWN GENETIC CONDITIONS.....	9
<i>Chest/Abdomen/Pelvis MRA</i> .....	9
<i>Brain/Neck/Chest/Abdomen/Pelvis MRA</i> .....	9
<b>OTHER COMBINATION STUDIES WITH PELVIS MRA.....</b>	<b>9</b>
ABDOMEN/PELVIS MRA .....	9
BRAIN/NECK/CHEST/ABDOMEN/PELVIS MRA.....	10
CHEST/ABDOMEN/PELVIS MRA.....	10
CHEST/ABDOMEN/PELVIS/LOWER EXTREMITY MRA.....	10
BRAIN/NECK/CHEST/ABDOMEN/PELVIS MRA.....	10
PELVIS MRA AND PELVIS MRI (OR CT) .....	11

<b>CODING AND STANDARDS .....</b>	<b>11</b>
CODES.....	11
APPLICABLE LINES OF BUSINESS .....	11
<b>BACKGROUND .....</b>	<b>12</b>
CONTRAINDICATIONS AND PREFERRED STUDIES .....	12
<b>SUMMARY OF EVIDENCE .....</b>	<b>12</b>
<b>ANALYSIS OF EVIDENCE.....</b>	<b>13</b>
<b>POLICY HISTORY .....</b>	<b>14</b>
<b>LEGAL AND COMPLIANCE .....</b>	<b>15</b>
GUIDELINE APPROVAL .....	15
<i>Committee</i> .....	15
DISCLAIMER .....	15
<b>REFERENCES.....</b>	<b>17</b>

## STATEMENT

### General Information

- *It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.*
- *Where a specific clinical indication is not directly addressed in this guideline, medical necessity determination will be made based on widely accepted standard of care criteria. These criteria are supported by evidence-based or peer-reviewed sources such as medical literature, societal guidelines and state/national recommendations.*
- *The guideline criteria in the following sections were developed utilizing evidence-based and peer-reviewed resources from medical publications and societal organization guidelines as well as from widely accepted standard of care, best practice recommendations.*

### Purpose

Magnetic resonance angiography (MRA) ~~and magnetic resonance venography (MRV)~~ generates images of the blood vessels (both arteries and veins) that can be evaluated for evidence of stenosis, occlusion, or aneurysms without use of ionizing radiation. It is used to evaluate the blood vessels of the pelvis.

### Special Note

When the criteria for imaging of peripheral vascular disease are met (see relevant guidelines), two separate authorizations are required: Abdomen MRA (CPT 74185) and one Lower Extremity MRA (CPT 73725). This will provide imaging of the abdomen, pelvis and both legs. A separate Pelvis MRA authorization is **NOT** required. Only one Lower Extremity MRA is required (not two).

## INDICATIONS FOR PELVIS MRA

### Abdominal Aortic Disease

#### ***Abdominal Aortic Aneurysm***

- ~~Suspected **Asymptomatic** abdominal aortic aneurysm (AAA) with **ALL** of the following:~~
  - ~~Prior ultrasound is inconclusive or insufficient~~
- ~~CT/CTA is **contraindicated or cannot be performed**~~
- Suspected or ~~known~~ **Asymptomatic** Abdominal Aortic Aneurysm (AAA) with **ALL** of the following:

- Prior ultrasound is inconclusive or insufficient
- A reason MRA is needed rather than CT/CTA is **contraindicated or cannot be performed** has been provided (e.g., complex vascular anatomy or suspected complications)
- The study is ordered at the appropriate ~~Typical AAA screening Intervals~~ surveillance interval <sup>(1)</sup>:
  - Aneurysm size 2.5-3 cm, every 10 years
  - Aneurysm size 3.0-3.9 cm, every 3 years
  - Aneurysm size 4.0-4.9 cm, annually
  - Aneurysm size 5.0-5.4 cm, every 6 months
- Known or suspected **Symptomatic-symptomatic** AAA ~~when CT/CTA is~~ **contraindicated or cannot be performed** <sup>(1,2)</sup>
  - Symptoms may include:
    - Abrupt onset of severe sharp or stabbing pain in the chest, back or abdomen (could indicate possible aneurysm rupture)
    - Acute abdominal or back pain with a pulsatile or epigastric mass
    - Acute abdominal or back pain and at high risk for aortic aneurysm and/or aortic syndrome (risk factors include hypertension, atherosclerosis, prior cardiac or aortic surgery, underlying aneurysm, connective tissue disorder (e.g., Marfan syndrome, vascular form of Ehlers-Danlos syndrome, Loeys-Dietz syndrome), and bicuspid aortic valve) <sup>(3)</sup>

## **Aortic Syndromes**

For initial diagnosis of suspected and follow-up of known aortic syndromes, including aortic dissection, intramural hematoma and penetrating atherosclerotic ulcer

- Frequency for follow up is as clinically indicated

## **Postoperative Follow-up of Aortic Repair** <sup>(1,2)</sup>

Follow-up for post-endovascular repair (EVAR) or open repair of AAA or abdominal extent of iliac artery aneurysms at the following intervals (CT preferred for routine follow-up):

- Routine, baseline post-EVAR study when a reason MRA rather than CT/CTA is needed has been provided (such as complex anatomy or suspected complications with any ONE of the following: **contraindicated or cannot be performed**:
  - Within one month of procedure
  - Continued follow up imaging at the following intervals:
    - If no endoleak or sac enlargement is seen:
      - Annually with past inconclusive or insufficient ~~monitor with~~ ultrasound

- ~~□ When ultrasound is abnormal or insufficient CT/MR can be using to monitor annually~~
  - Every 5 years ~~monitor with CT/MR (inconclusive or insufficient ultrasound not required at the 5-year interval)~~
  - If type II endoleak or sac enlargement is seen at any point in time (US not needed):
    - ~~Monitor e~~Every 6 months x 2 years, then annually (does not require US)
- Routine follow up after open repair of AAA when a reason MRA is needed rather than CT/CTA is **contraindicated or cannot be performed** has been provided (e.g., complex vascular anatomy or suspected complications) with and **ONE** of the following<sup>(1)</sup>:
- Within 1 year postoperatively then
- Annually with past inconclusive or insufficient monitor with ultrasound
- ~~○ When US is abnormal or insufficient CT/MR can be used to monitor annually~~
- Every 5 years (inconclusive or insufficient ultrasound not required at the 5-year interval) monitor with CT/MR
- If symptomatic or imaging shows increasing, or new findings related to stent graft – more frequent imaging may be needed as clinically indicated
- Suspected complication (e.g., such as new-onset lower extremity claudication, ischemia, or reduction in ABI after aneurysm repair)
- Evaluation of endovascular/interventional abdominal vascular procedures for luminal patency versus restenosis due to conditions such as atherosclerosis, thromboembolism, and intimal hyperplasia
- Evaluation of post-operative complications, e.g., such as pseudoaneurysms, related to surgical bypass grafts, vascular stents, and stent-grafts in the peritoneal cavity

## Ischemia or Hemorrhage

- To determine the vascular source of retroperitoneal hematoma or hemorrhage when CT is insufficient to determine the source and CTA is **contraindicated or cannot be performed**; (CT rather than MRA/CTA is the modality of choice for diagnosing hemorrhage)<sup>(4)</sup>
- Evaluation of known or suspected mesenteric ischemia/ischemic colitis when CTA is **contraindicated or cannot be performed**<sup>(5)</sup>

## Other Vascular Abnormalities of the Pelvis

- Initial evaluation of inconclusive vascular findings on prior imaging
- For evaluation or monitoring of pelvic vascular disease when ultrasound is inconclusive of non-aortic large vessel pelvic vascular disease (sSuch as aneurysm, dissection, arteriovenous malformations (AVM), vascular fistula, intramural hematoma, compression

syndromes and vasculitis) and the findings are reasonably expected to be limited to the pelvis <sup>(6)</sup>

- For assessment in patients with spontaneous coronary artery dissection (SCAD), can be done at time of coronary angiography <sup>(7,8)</sup>
- Suspected complications of known aneurysm as evidenced by clinical findings such as new onset of pelvic pain
- For patients with fibromuscular dysplasia (FMD) <sup>(9,10)</sup>:
  - One-time vascular study from brain to pelvis
- Takayasu's Arteritis <sup>(11)</sup>:
  - At initial diagnosis
  - Every 6 months for the first 2 years while on therapy
  - Annually after the first 2 years

## Venous Disease

- Suspected ~~pelvic vascular disease or~~ pelvic congestive syndrome (including May-Thurner and nutcracker syndromes) when findings on ultrasound are indeterminate is indeterminant (with no contraindication to CT is needed) NO CONTRAINDICATIONS TO CT <sup>(12)</sup>
- For acute unilateral (or symmetric) lower extremity edema with negative or inconclusive doppler US and CT <sup>(13)</sup>
- For chronic (greater than 3 months) Unexplained lower extremity edema (typically unilateral (or asymmetric) lower extremity edema and suspicion of malignant cause when with negative or inconclusive Abdomen and/or Pelvis CT (or Pelvis CT) is negative or inconclusive <sup>(13)</sup>
- Venous thrombosis (including inferior vena cava thrombosis) if previous studies (such as ultrasound) have not resulted in a clear diagnosis <sup>(14,15)</sup>
- ~~Known/suspected May-Thurner Syndrome (iliac vein compression syndrome) when CTA V is contraindicated or cannot be performed~~ <sup>(15,16)</sup>
- For pregnant women with suspected deep venous thrombosis (DVT) (including suspected extension to the iliac vein) after compression ultrasound <sup>(16)</sup>

## Evaluation of Tumor

- When needed for clarification of vascular involvement from tumor <sup>(17)</sup>

~~FOR IMAGING OF THE DEEP INFERIOR EPIGASTRIC ARTERIES PRIOR TO BREAST RECONSTRUCTIVE~~

## ~~SURGERY~~ <sup>(18)</sup>

# ~~PREOPERATIVE EVALUATION AND/OR POSTOPERATIVE ASSESSMENT PRE-PROCEDURAL EVALUATION~~

When otherwise specified in the guideline:

### Preoperative Evaluation:

- Evaluation prior to interventional vascular for luminal patency versus restenosis due to conditions such as atherosclerosis, thromboembolism, and intimal hyperplasia
- Evaluation prior to endovascular aneurysm repair (EVAR) <sup>(19)</sup>
- Evaluation prior to Transcatheter Aortic Valve Replacement (TAVR) CTA is **contraindicated or cannot be performed** <sup>(20)</sup>
- For imaging of the deep inferior epigastric arteries prior to breast reconstructive surgery <sup>(18)</sup>
- Evaluation of vascular anatomy prior to solid organ transplantation
- Prior to uterine artery embolization for fibroids <sup>(21)</sup>
- For evaluation of erectile dysfunction when a vascular cause is confirmed by doppler ultrasound, revascularization is planned and there is a contraindication to selective internal pudendal angiography (SIPA) <sup>(22)</sup>
- Imaging of the area requested is needed to develop a surgical plan

### Postoperative Evaluation

- Follow-up study may be needed to help evaluate a patient's progress after treatment, procedure, intervention, or surgery. Documentation requires a medical reason that clearly indicates why additional imaging is needed for the type and area(s) requested.
- Endovascular/interventional vascular procedures for luminal patency versus restenosis due to conditions such as atherosclerosis, thromboembolism, and intimal hyperplasia
- Post-operative complications (e.g., pseudoaneurysms related to surgical bypass grafts, vascular stents, and stent-grafts in the pelvis)
- Post-operative complications of renal transplant allograft <sup>(23)</sup>
- Known or suspected complications
- A clinical reason is provided how imaging may change management

**NOTE:** This section applies only within the first few months following surgery

## FURTHER EVALUATION OF INDETERMINATE FINDINGS

Unless follow-up is otherwise specified within the guideline

- For initial evaluation of an inconclusive finding on a prior imaging report that requires further clarification
- One follow-up exam of a prior indeterminate MR/CT finding to ensure no suspicious interval change has occurred. (No further surveillance unless specified as highly suspicious or change was found on last follow-up exam)

## IMAGING OF KNOWN GENETIC CONDITIONS SYNDROME AND RARE DISEASES

- ~~● For patients with fibromuscular dysplasia (FMD) <sup>(Gornik 2010, Kosov 2023)</sup>~~
- ~~● One-time vascular study from brain to pelvis~~
- Vascular Ehlers-Danlos syndrome (vEDS) <sup>(24)</sup>:
  - Every 18 months (including at diagnosis) and then every 18 months OR
  - As clinically indicated to follow known ~~More frequently if~~ vascular abnormalities ~~are found~~
- Marfan syndrome <sup>(25)</sup>:
  - Every 3 years (including at diagnosis) and then every 3 years
  - More frequently (annually) if **EITHER**: history of dissection, dilation of aorta beyond aortic root **OR** aortic root/ascending aorta are not adequately visualized on TTE (i.e. advanced imaging is needed to monitor the thoracic aorta)
- Loeys-Dietz <sup>(26)</sup>:
  - Every two years (including at diagnosis) and then every two years
  - More frequently if abnormalities are found
- Williams Syndrome <sup>(27)</sup>:
  - Abnormal ~~When there is concern for~~ vascular disease exam or imaging findings (such as concern for renal artery stenosis) ~~based on abnormal exam or imaging findings (such as~~ diminished pulses, bruits or signs of ~~diffuse~~ thoracic aortic stenosis)
- Neurofibromatosis Type 1 (NF-1) <sup>(28)</sup>:
  - Development of hypertension (including concern for renal artery stenosis)
- ~~● Takayasu's Arteritis <sup>(Joseph 2023)</sup>~~
  - ~~○ At initial diagnosis~~

- ~~○ Every 6 months for the first 2 years while on therapy~~
- ~~— Annually after the first 2 years~~
- For evaluation at diagnosis then as clinically indicated

- For other syndromes and rare diseases not otherwise addressed in the guideline, coverage is based on a case-by-case basis using societal guidance

## **Combination Studies for Known Genetic Conditions**

**NOTE:** When medical necessity is met for an individual study AND conscious sedation is required (such as for young pediatric patients or patients with significant developmental delay), the entire combination is indicated)

### **Chest/Abdomen/Pelvis MRA**

- Marfan syndrome <sup>(25)</sup>
  - Every 3 years (including at diagnosis) and every 3 years
  - More frequently (annually) if EITHER: history of dissection, dilation of aorta beyond aortic root OR aortic root/ascending aorta are not adequately visualized on TTE (i.e. advanced imaging is needed to monitor the thoracic aorta)
- Williams Syndrome <sup>(27)</sup>
  - Abnormal. When there is concern for vascular exam or imaging findings disease (such as including concern for renal artery stenosis.) based on abnormal exam or imaging findings (such as diminished pulses, bruits or signs of diffuse diffuse thoracic aortic stenosis)

### **Brain/Neck/Chest/Abdomen/Pelvis MRA**

- Vascular Ehlers-Danlos syndrome: At diagnosis and then every 18 months; more frequently if abnormalities are found <sup>(24)</sup>
- Loeys-Dietz: at diagnosis and then every two years, more frequently if abnormalities are found <sup>(26)</sup>

## **OTHER COMBINATION STUDIES WITH PELVIS MRA**

**NOTE:** When medical necessity is met for an individual study AND conscious sedation is required (such as for young pediatric patients or patients with significant developmental delay), the entire combination is indicated)

### **Abdomen/Pelvis MRA**

- As a dedicated CPT code does not exist for Abdomen and Pelvis MRA, when a disease process is reasonably expected to involve both the abdomen and pelvis AND the guideline criteria have been met, two separate authorizations are required: Abdomen

MRA (CPT code 74185) and Pelvis MRA (CPT 72198)

## Brain/Neck/Chest/Abdomen/Pelvis MRA

- For patients with fibromuscular dysplasia (FMD), a one-time vascular study from brain to pelvis is indicated <sup>(9,10)</sup>
- ~~• Vascular Ehlers-Danlos syndrome: At diagnosis and then every 18 months; more frequently if abnormalities are found <sup>(28,29)</sup>~~
- ~~• Loeys-Dietz: at diagnosis and then every two years; more frequently if abnormalities are found <sup>(32)</sup>~~ For assessment in patients with spontaneous coronary artery dissection (SCAD), (SCAD is a common initial diagnostic event for underlying fibromuscular dysplasia (FMD)) can be done at time of coronary angiography <sup>(7)</sup>

**NOTE:** Body vascular imaging for SCAD can be performed at the time of coronary angiography

## Chest/Abdomen/Pelvis MRA

- Evaluation prior to endovascular aneurysm repair (EVAR) when thoracic involvement is present when CTA is contraindicated or cannot be performed <sup>(19)</sup>
- Evaluation prior to Transcatheter Aortic Valve Replacement (TAVR) when CTA is **contraindicated or cannot be performed** <sup>(20)</sup>
- ~~• Marfan syndrome <sup>(30)</sup>
  - ~~○ At diagnosis and every 3 years~~
  - ~~○ More frequently (annually) if **EITHER**: history of dissection, dilation of aorta beyond aortic root **OR** aortic root/ascending aorta are not adequately visualized on TTE (i.e. advanced imaging is needed to monitor the thoracic aorta) <sup>(2,34)</sup>~~~~
- ~~• Williams Syndrome <sup>(33)</sup>~~
- ~~When there is concern for vascular disease (including renal artery stenosis) based on abnormal exam or imaging findings (such as diminished pulses, bruits or signs of diffuse thoracic aortic stenosis) Acute aortic dissection <sup>(29)</sup>~~
- Significant post-traumatic or post-procedural vascular complications reasonably expected to involve the chest, abdomen and pelvis

## Chest/Abdomen/Pelvis/Lower Extremity MRA

- To evaluate for an embolic source of lower extremity thromboembolic vascular disease
  - NOTE: Echocardiogram is also indicated as the heart is the most commonly reported source of lower extremity emboli.

## Brain/Neck/Chest/Abdomen/Pelvis MRA

- Takayasu's Arteritis For evaluation at diagnosis then as clinically indicated <sup>(11)</sup>:

- [At initial diagnosis](#)
- [Every 6 months for the first 2 years while on therapy](#)
- [Annually after the first 2 years](#)

## Pelvis MRA and Pelvis MRI (or CT)

- When needed for clarification of vascular ~~invasion~~ [involvement](#) from tumor (including suspected renal vein thrombosis) <sup>(30)</sup>
- Prior to uterine artery embolization for fibroids <sup>(31)</sup>

### ~~Further Evaluation of Indeterminate Findings on Prior Imaging~~

~~Unless follow-up is otherwise specified within the guideline~~

~~For initial evaluation of an inconclusive finding on a prior imaging report that requires further clarification~~

~~One follow-up exam of a prior indeterminate MR/CT finding to ensure no suspicious interval change has occurred. (No further surveillance unless specified as highly suspicious or change was found on last follow-up exam)~~

## CODING AND STANDARDS

### ~~Coding~~

### ~~CPT Codes~~

72198

### Applicable Lines of Business

<input checked="" type="checkbox"/>	CHIP (Children's Health Insurance Program)
<input checked="" type="checkbox"/>	Commercial
<input checked="" type="checkbox"/>	Exchange/Marketplace
<input checked="" type="checkbox"/>	Medicaid
<input checked="" type="checkbox"/> <input type="checkbox"/>	Medicare Advantage

## BACKGROUND

### ~~Abdominal Aneurysms and General Guidelines for Follow-Up~~

~~The normal diameter of the suprarenal abdominal aorta is 3.0 cm and that of the infrarenal is 2.0 cm. Aneurysmal dilation of the infrarenal aorta is defined as diameter  $\geq$  3.0 cm or dilatation of the aorta  $\geq$  1.5x the normal diameter.~~

### ~~Iliac Aneurysm Ultrasound Screening Intervals~~

- ~~• Aneurysm size 2.0-2.9 cm, every 3 years~~
- ~~• Aneurysm size 3.0-3.4 cm, annually~~
- ~~• Aneurysm size  $>$  3.5 cm, every 6 months<sup>(3)</sup>~~

### ~~MRI/CT and Acute Hemorrhage~~

~~MRI is not indicated and MRA/MRV (MR Angiography/Venography) is rarely indicated for evaluation of intraperitoneal or retroperitoneal hemorrhage, particularly in the acute setting. CT is the study of choice due to its availability, speed of the study, and less susceptibility to artifact from patient motion. Advances in technology have allowed conventional CT to detect hematomas and the source of acute vascular extravasation. In special cases, finer vascular detail to assess the specific source vessel responsible for hemorrhage may require the use of CTA (e.g., for the diagnosis of lower gastrointestinal bleeding).<sup>(37)</sup>~~

~~MRA/MRV is often utilized in non-acute situations to assess vascular structure involved in atherosclerotic disease with associated complications, vasculitis, venous thrombosis, vascular congestion, or tumor invasion. Although some may be associated with hemorrhage, it is usually not the primary reason why MRI/MRA/MRV is selected for the evaluation. A special condition where MRI may be superior to CT for evaluating hemorrhage is to detect an underlying neoplasm as the cause of bleeding.<sup>(4)</sup>~~

### ~~Contraindications and Preferred Studies~~

- ~~• Contraindications and reasons why a CT/CTA cannot be performed may include: impaired renal function, significant allergy to IV contrast, pregnancy (depending on trimester)~~
- ~~• Contraindications and reasons why an MRI/MRA cannot be performed may include: impaired renal function, claustrophobia, non-MRI compatible devices (such as non-compatible defibrillator or pacemaker), metallic fragments in a high-risk location, patient exceeds weight limit/dimensions of MRI machine~~

## SUMMARY OF EVIDENCE

[2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines](#)<sup>(1)</sup>

**Study Design:** This document is a guideline report from the American Heart Association (AHA) and American College of Cardiology (ACC) Joint Committee on Clinical Practice Guidelines. It provides recommendations for the diagnosis and management of aortic disease based on a comprehensive literature search and evidence review.

**Target Population:** The guidelines are intended for clinicians managing patients with aortic disease, including asymptomatic, stable symptomatic, and acute aortic syndromes.

**Key Factors:** Recommendations cover genetic evaluation, family screening, medical therapy, endovascular and surgical treatment, and long-term surveillance. Emphasis on involving patients and multidisciplinary teams in determining optimal therapies, especially for pregnant patients. Guidelines for computed tomography, magnetic resonance imaging, and echocardiographic imaging. Lowered thresholds for surgical intervention in specific scenarios. Importance of institutional volume and expertise in patient outcomes.

### **ACR Appropriateness Criteria® Radiologic Management of Mesenteric Ischemia: 2022 Update** <sup>(5)</sup>

**Study Design:** This is an update on the ACR Appropriateness Criteria for the radiologic management of mesenteric ischemia.

**Target Population:** Patients with mesenteric ischemia, including acute and chronic cases.

**Key Factors:** The article discusses various endovascular and surgical interventions for mesenteric ischemia, including embolectomy, thrombolysis, angioplasty, and stent placement. It provides evidence-based guidelines for the appropriate use of these interventions based on the clinical scenario, such as the presence of embolus, atherosclerotic plaque, or venous mesenteric ischemia. The guidelines aim to improve patient outcomes by recommending the most suitable imaging and treatment procedures.

### **Insights into pelvic venous disorders** <sup>(12)</sup>

**Study Design:** This is a review article that focuses on pelvic venous disorders (PeVD), also known as pelvic congestion syndrome (PCS).

**Target Population:** Mainly young women between the ages of 20 and 50 years, who experience chronic pelvic pain (CPP) due to venous-related symptoms.

**Key Factors:** The article discusses the multifactorial etiology of PeVD, including genetic predisposition, anatomical abnormalities, and hormonal factors. It emphasizes the importance of imaging in diagnosing PeVD and proposes a new classification scheme to assist clinical decision-making. The review also covers various therapeutic approaches, including minimally invasive techniques, and highlights the need for standardized guidelines for treatment.

## **ANALYSIS OF EVIDENCE**

**Analysis** <sup>(1,5,12)</sup>:

In summary, while all three articles share common themes such as the importance of imaging, multidisciplinary approaches, and minimally invasive techniques, they differ in their specific focus, treatment recommendations, and classification systems. Each article provides valuable insights into the management of their respective conditions, contributing to the overall understanding of vascular disorders.

### **Shared Conclusions**

- **Importance of Imaging and Diagnostic Techniques:** All three articles emphasize the critical role of imaging in diagnosing and managing vascular conditions. Discusses the use of CT, MRI, and echocardiography for aortic disease. Highlights the use of CT, MRI, and ultrasound for diagnosing mesenteric ischemia. Focuses on various imaging modalities like ultrasound, CT, and MRI for diagnosing pelvic venous disorders.
- **Multidisciplinary Approach:** The need for a multidisciplinary team is a common theme. Importance of a multidisciplinary aortic team for optimal patient outcomes, involvement of various specialists in managing mesenteric ischemia, and also advocates for a multidisciplinary approach to manage pelvic venous disorders effectively.
- **Emphasis on Minimally Invasive Techniques:** All three articles highlight the preference for minimally invasive techniques.

## **POLICY HISTORY**

<b>Date</b>	<b>Summary</b>
<u>July 2025</u>	<ul style="list-style-type: none"> <li>● <u>Adjusted guideline title-name spelled out</u></li> <li>● <u>Added a Summary of Evidence and Analysis of Evidence</u></li> <li>● Moved further evaluation section below Preop</li> </ul>
<u>June 2025</u>	<ul style="list-style-type: none"> <li>● <u>This guideline replaces Evolent Clinical Guideline 039 for Pelvis MRA/MRV (Angiography/Venography)</u></li> <li>● <u>Added in general information statement regarding guideline criteria development by reputable sources, standard of care, and best practices</u></li> <li>● <u>Moved AAA screening intervals from background to AAA indications section</u></li> <li>● <u>Moved FMD and Takayasu’s arteritis to Other Vascular Abnormalities section</u></li> <li>● <u>Adjusted the language in the Venous Disease section for pelvic congestion syndrome to include nutcracker syndrome</u></li> <li>● <u>Added and adjusted language in the Venous Disease section for acute and chronic unilateral lower extremity edema</u></li> </ul>

Date	Summary
	<ul style="list-style-type: none"> <li>● <u>Updated language in the preoperative/postoperative section</u></li> <li>● <u>Segment added to the combination's studies about if the required use of conscious sedation is needed the entire combination is indicated</u></li> <li>● <u>Genetics section surveillance language adjusted in vEDS, Marfan Syndrome, and Loey's Dietz Syndrome sections</u></li> <li>● <u>Combinations Studies for Known Genetic Diseases section was added</u></li> <li>● <u>Brain added to the Neck/Chest/Abdomen and Pelvis CTA combo with surveillance added to Takayasu's arteritis</u></li> <li>● <u>Applicable Line of Business adjusted – Medicare checked</u></li> <li>● <u>Background reduced</u></li> </ul>
April 2024	<ul style="list-style-type: none"> <li>● Separated out aortic syndromes to be more clear</li> <li>● EVAR studies clarified order of which studies would be ordered</li> <li>● Renal artery stenosis: updated per new clinical guidance</li> <li>● Added Genetic Syndromes and Tumors Section</li> <li>● Statement put in all Guidelines for contraindications put in indications and background sections</li> <li>● Combo section adjusted and made uniform</li> <li>● Updated references and background sections</li> </ul>

## LEGAL AND COMPLIANCE

### Guideline Approval

#### Committee

Reviewed / Approved by Evolent Specialty Services Clinical Guideline Review Committee

#### Disclaimer

*Evolent Clinical Guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Evolent uses Clinical Guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of*



their health care coverage or government program. Individual members' health care coverage may not utilize some Evolent Clinical Guidelines. Evolent clinical guidelines contain guidance that requires prior authorization and service limitations. A list of procedure codes, services or drugs may not be all inclusive and does not imply that a service or drug is a covered or non-covered service or drug. Evolent reserves the right to review and update this Clinical Guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. Members should contact their Plan customer service representative for specific coverage information.

Evolent Clinical Guidelines are comprehensive and inclusive of various procedural applications for each service type. Our guidelines may be used to supplement Medicare criteria when such criteria is not fully established. When Medicare criteria is determined to not be fully established, we only reference the relevant portion of the corresponding Evolent Clinical Guideline that is applicable to the specific service or item requested in order to determine medical necessity.

## REFERENCES

1. Isselbacher EM, Preventza O, Hamilton Black J, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;146(24):e334-e482. doi:10.1161/CIR.0000000000001106
2. Chaikof EL, Dalman RL, Eskandari MK, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. *J Vasc Surg*. 2018;67(1):2-77.e2. doi:10.1016/j.jvs.2017.10.044
3. Wanhainen A, Van Herzele I, Bastos Goncalves F, et al. Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms. *European Journal of Vascular and Endovascular Surgery*. 2024;67(2):192-331. doi:10.1016/j.ejvs.2023.11.002
4. Verma N, Steigner ML, Aghayev A, et al. ACR Appropriateness Criteria® Suspected Retroperitoneal Bleed. *Journal of the American College of Radiology*. 2021;18(11):S482-S487. doi:10.1016/j.jacr.2021.09.003
5. Lam A, Kim YJ, Fidelman N, et al. ACR Appropriateness Criteria® Radiologic Management of Mesenteric Ischemia: 2022 Update. *Journal of the American College of Radiology*. 2022;19(11):S433-S444. doi:10.1016/j.jacr.2022.09.006
6. Juntermanns B, Bernheim J, Karaindros K, Walensi M, Hoffmann JN. Visceral artery aneurysms. *Gefässchirurgie*. 2018;23(S1):19-22. doi:10.1007/s00772-018-0384-x
7. Teruzzi G, Santagostino Baldi G, Gili S, Guarnieri G, Montorsi P, Trabattoni D. Spontaneous Coronary Artery Dissections: A Systematic Review. *J Clin Med*. 2021;10(24):5925. doi:10.3390/jcm10245925
8. Hayes SN, Tweet MS, Adlam D, et al. Spontaneous Coronary Artery Dissection. *J Am Coll Cardiol*. 2020;76(8):961-984. doi:10.1016/j.jacc.2020.05.084
9. Gornik HL, Persu A, Adlam D, et al. First International Consensus on the diagnosis and management of fibromuscular dysplasia. *Vascular Medicine*. 2019;24(2):164-189. doi:10.1177/1358863X18821816
10. Kesav P, Raj DM, John S. Cerebrovascular Fibromuscular Dysplasia – A Practical Review. *Vasc Health Risk Manag*. 2023;19:543-556. doi:10.2147/VHRM.S388257
11. Joseph G, Goel R, Thomson VS, Joseph E, Danda D. Takayasu Arteritis. *J Am Coll Cardiol*. 2023;81(2):172-186. doi:10.1016/j.jacc.2022.09.051
12. Rezaei-Kalantari K, Fahrni G, Rotzinger DC, Qanadli SD. Insights into pelvic venous disorders. *Front Cardiovasc Med*. 2023;10. doi:10.3389/fcvm.2023.1102063
13. Gasparis AP, Kim PS, Dean SM, Khilnani NM, Labropoulos N. Diagnostic approach to lower limb edema. *Phlebology: The Journal of Venous Disease*. 2020;35(9):650-655. doi:10.1177/0268355520938283
14. Aw-Zoretic J, Collins J. Considerations for Imaging the Inferior Vena Cava (IVC) with/without IVC Filters. *Semin Intervent Radiol*. 2016;33(2):109-121. doi:10.1055/s-0036-1583207

15. Hanley M, Steigner ML, Ahmed O, et al. ACR Appropriateness Criteria® Suspected Lower Extremity Deep Vein Thrombosis. *Journal of the American College of Radiology*. 2018;15(11):S413-S417. doi:10.1016/j.jacr.2018.09.028
16. Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. *Blood Adv*. 2018;2(22):3317-3359. doi:10.1182/bloodadvances.2018024802
17. Zucker EJ, Ganguli S, Ghoshhajra BB, Gupta R, Prabhakar AM. Imaging of venous compression syndromes. *Cardiovasc Diagn Ther*. 2016;6(6):519-532. doi:10.21037/cdt.2016.11.19
18. Singh N, Aghayev A, Ahmad S, et al. ACR Appropriateness Criteria® Imaging of Deep Inferior Epigastric Arteries for Surgical Planning (Breast Reconstruction Surgery): 2022 Update. *Journal of the American College of Radiology*. 2022;19(11):S357-S363. doi:10.1016/j.jacr.2022.09.004
19. Francois CJ, Skulborstad EP, Majdalany BS, et al. ACR Appropriateness Criteria® Abdominal Aortic Aneurysm: Interventional Planning and Follow-Up. *Journal of the American College of Radiology*. 2018;15(5):S2-S12. doi:10.1016/j.jacr.2018.03.008
20. Hedgire SS, Saboo SS, Galizia MS, et al. ACR Appropriateness Criteria® Preprocedural Planning for Transcatheter Aortic Valve Replacement: 2023 Update. *Journal of the American College of Radiology*. 2023;20(11):S501-S512. doi:10.1016/j.jacr.2023.08.009
21. Kubik-Huch RA, Weston M, Nougaret S, et al. European Society of Urogenital Radiology (ESUR) Guidelines: MR Imaging of Leiomyomas. *Eur Radiol*. 2018;28(8):3125-3137. doi:10.1007/s00330-017-5157-5
22. Burnett AL, Nehra A, Breau RH, et al. Erectile Dysfunction: AUA Guideline. *Journal of Urology*. 2018;200(3):633-641. doi:10.1016/j.juro.2018.05.004
23. Serhal A, Aouad P, Serhal M, et al. Evaluation of Renal Allograft Vasculature Using Non-contrast 3D Inversion Recovery Balanced Steady-state Free Precession MRA and 2D Quiescent-interval Slice-selective MRA. *Explor Res Hypothesis Med*. 2021;6(3):90-98. doi:10.14218/ERHM.2021.00011
24. Byers PH. Vascular Ehlers-Danlos Syndrome. *GeneReviews*®. Published online April 10, 2025. <https://www.ncbi.nlm.nih.gov/books/NBK1494/>
25. Dietz H. FBN1-Related Marfan Syndrome. *GeneReviews*®. Published online February 17, 2022. <https://www.ncbi.nlm.nih.gov/books/NBK1335/>
26. Loeyls BL, Dietz HC. Loeyls-Dietz Syndrome. *GeneReviews*®. Published online September 12, 2024. <https://www.ncbi.nlm.nih.gov/books/NBK1133/>
27. Morris CA. Williams Syndrome. *GeneReviews*®. Published online April 13, 2023. <https://www.ncbi.nlm.nih.gov/books/NBK1249/>
28. Friedman J. Neurofibromatosis 1. *GeneReviews*®. Published online April 3, 2025. <https://www.ncbi.nlm.nih.gov/books/NBK1109/>

29. Kicska GA, Hurwitz Koweek LM, Ghoshhajra BB, et al. ACR Appropriateness Criteria® Suspected Acute Aortic Syndrome. *Journal of the American College of Radiology*. 2021;18(11):S474-S481. doi:10.1016/j.jacr.2021.09.004
30. Čertík B, Třeška V, Moláček J, Šulc R. How to proceed in the case of a tumour thrombus in the inferior vena cava with renal cell carcinoma. *Cor Vasa*. 2015;57(2):e95-e100. doi:10.1016/j.crvasa.2015.02.015
31. Maciel C, Tang YZ, Sahdev A, Madureira AM, Vilares Morgado P. Preprocedural MRI and MRA in planning fibroid embolization. *Diagnostic and Interventional Radiology*. 2017;23(2):163-171. doi:10.5152/dir.2016.16623